HOME > Investors >
ViroMed reports operating profit increased by 342% from previous year
ViroMed Publishes Results from Critical Limb Ischemia (CLI) Phase II Clinical Study
Texas Heart Institute announces PAD phase II results on "Gene Therapy"
ViroMed and bluebird bio Enter into License Agreement for Novel Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy
US FDA Approves VM202 for Phase III Clinical Study of Chronic Non-Healing Ischemic Diabetic Foot Ulcer by US FDA